Hoth Therapeutics, Inc. (RKTO) — Financial statements
Income statement, balance sheet, and cash flow for Hoth Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 6↑83.0% | 3↓6.6% | 3↓29.4% | 5↓34.5% | 8 | |
| General & Administrative Expenses | 6↑29.2% | 5↑17.9% | 4↓31.3% | 6↓6.7% | 7 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 6↑29.2% | 5↑17.9% | 4↓31.3% | 6↓6.7% | 7 | |
| Other Expenses | -1 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 11↑35.2% | 8↑6.8% | 8↓30.5% | 11↓21.5% | 14 | |
| Total Costs & Expenses | 11↑35.2% | 8↑6.8% | 8↓30.5% | 11↓21.5% | 14 | |
| Operating Results | ||||||
| Operating Income | -11↓35.2% | -8↓6.8% | -8↑30.5% | -11↑21.5% | -14 | |
| Depreciation & Amortization | 0.00↓100.0% | 8↑6.8% | 8↓30.5% | 11 | 0.00 | |
| EBITDA | -11↓41051.1% | 0.03↑117.7% | -0.15 | 0.00↑100.0% | -14 | |
| EBIT | -11↓35.7% | -8↓4.4% | -8↑29.1% | -11↑21.5% | -14 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓97.5% | 0.03↓46.5% | 0.05↑117.3% | -0.30 | 0.00 | |
| Interest Income | 0.00↓97.5% | 0.03↓46.5% | 0.05↑712.7% | 0.01 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.31 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -0.03↓117.7% | 0.15 | 0.00 | 0.00 | |
| Other Income / Expenses | -1↓5106.8% | 0.03↑117.7% | -0.15↑50.0% | -0.31↓44.3% | -0.21 | |
| Income Before Tax | -12↓52.3% | -8↓4.4% | -8↑31.0% | -11↑20.6% | -14 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -12↓52.3% | -8↓4.4% | -8↑31.0% | -11↑20.6% | -14 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -12↓52.3% | -8↓4.4% | -8↑31.0% | -11↑20.6% | -14 | |
| Bottom-Line Net Income | -12↓52.3% | -8↓4.4% | -8↑31.0% | -11↑20.6% | -14 | |
| EPS (Basic) | -0.90↑29.7% | -1.28↑44.3% | -2.30↑75.8% | -9.50↑40.7% | -16.03 | |
| EPS (Diluted) | -0.90↑29.7% | -1.28↑44.3% | -2.30↑75.8% | -9.50↑40.7% | -16.03 | |
| Weighted Average Shares | 14↑116.6% | 6↑87.0% | 3↑184.7% | 1↑34.1% | 0.89 | |
| Weighted Average Diluted Shares | 14↑116.6% | 6↑87.0% | 3↑184.7% | 1↑34.1% | 0.89 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.